Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431572 · ClinicalTrials.gov registry record · NA
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02431572: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02431572 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02431572, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called \[11C\] PBR28a, which is also known as peripheral benzodiazepine receptors (PBR), or PBR-PET.
Interventions
- OTHER PBR PET
- BIOLOGICAL Cancer Immunotherapy
- RADIATION Radiation and chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431572
The ClinicalTrials.gov registry entry for NCT02431572 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PBR PET is the first listed.
NCT02431572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431572 about?
NCT02431572 is a clinical study titled "A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy". This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called \[11C\] PBR28a, which is also known as peripheral benzodiazepine receptors (PBR), or PBR-PET.
What is the current status of trial NCT02431572?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2015-05. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02431572?
The interventions under investigation include: PBR PET (OTHER), Cancer Immunotherapy (BIOLOGICAL), Radiation and chemotherapy (RADIATION).
Who is sponsoring clinical trial NCT02431572?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.